The Precision Peptide Company has placed an order for 20,000 units of its Thymosin Alpha-1 transdermal patch, its first commercial production run of the product, the Vancouver-based company announced on October 7.

Thymosin alpha-1, abbreviated TA1, is a peptide that occurs naturally in the thymus and has been studied for immune-modulating properties. The company says each patch is formulated to deliver 2 mg of TA1, and that the product is designed to be worn on the skin with no injection, no reconstitution and no dose measurement by the user.

Why the patch format matters

The needle is the pitch. In the company's own framing, injection has been the biggest barrier to TA1, and a wearable format removes the step that keeps most consumers away from peptides entirely. That is a real commercial insight, and it is why this category keeps attracting money.

It is also the second time the company has moved a patch from testing into a production order, following its BPC-157 patch. Management calls that evidence the development model is repeatable, which is a claim about manufacturing cadence rather than about the product working.

What the evidence actually covers

Here is the part worth slowing down for. The company cites a 2025 systematic review and meta-analysis of TA1, and notes in the same release that every clinical study included in that review administered the peptide by subcutaneous injection. The review did not evaluate the patch, which the company says remains under development and testing.

So the published evidence base concerns a different route of administration than the product being manufactured. Whether a 2 mg dose crosses skin in any comparable way is exactly the question the cited literature does not answer, and no trial of the patch itself is described anywhere in the announcement.

Timing and listing details

The full run will be manufactured and tested in the United States, with finished units expected in January 2027 and commercial release to follow, subject to final quality review. The company trades as CSE: BPC and OTCQB: PNGAF.

Bottom line

Based on its own review of available products, the company believes it could be among the first to market with a TA1 transdermal patch. First to market is a position, not a result, and the result still depends on data nobody has published.